



# TUBERCULOSIS PROFILE 2077/078

Estimates of TB burden, 2076/77	Number	Rate (per 100000 Population)
Total TB incidence	69000	235 (139-356)
HIV positive TB incidence	1400	4.6(1.4-9.9)
MDR/RR-TB incidence	2200	7.6 (3.1-14)
HIV negative TB mortality	16000	55 (25-96)
HIV positive TB mortality	210	0.74 (0.34-1.3)

Source- Global TB Report 2021, WHO

Estimated proportion of TB cases with MDR/RR-TB, 2077/78	
New cases	2.2% (1.1-3.6)
Previously treated cases	15% (9.6-22)

Source- Global TB Report 2021, WHO

TB case notifications, 2077/78	
Total new and relapse	28182
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	72%
- % pulmonary	71%
- % bacteriologically confirmed	57%
- % children aged 0-14 years	6.6%
- % women	38%
- % men	62%
Total cases notified	28677

Source- HMIS data FY 2020/21

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2076/77	40% (26-67)
TB patients facing catastrophic total costs	-
TB Case fatality ratio (estimated mortality/estimated incidence), 2076/77	25% (9-46)

TB/HIV care in new and relapse TB patients, 2077/78	Number	(%)
Patients with known HIV-status who are HIV-positive on antiretroviral therapy	162	0.8%
	144	89%

Source- HMIS data FY 2020/21

Drug-resistant TB care, 2077/78	
% of bacteriologically confirmed TB cases tested for rifampicin resistance	
New cases	82%
Previously treated cases(Including Relapse)	90%
Laboratory-confirmed cases	MDR/RR-TB: 674, XDR-TB:13
Patients started on treatment	MDR/RR-TB: 410, XDR-TB: 8
MDR/RR-TB cases tested for resistance to second-line drugs	297






Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2076/77	91%	26,889
Previously treated cases, excluding relapse, registered in 2076/77	85%	342
MDR/RR-TB cases started on second-line treatment in 2075/76	72%	326
XDR-TB cases started on second-line treatment in 2075/76	80%	30

Source- NTPMIS and HMIS data FY 2020/21

TB preventive treatment, 2077/78	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged <5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	64%

Source- HMIS data FY 2020/21

TB financing, 2077/78	Funding Source	(NPR Million)
National TB budget	Nepal GoV:	473.50
	Global Fund	196.60
	WHO and other Partners (poolfund)	59.20



## BURDEN OF TB IN NEPAL

**28,677** TB cases Notified in NTP (2021)

TB is the **top ten leading** causes of death in Nepal

Almost **half** of Nepal's population are infected with TB

**Every Year** (Estimated)

**69,000** New TB Cases

**Male: 67%**

**Female: 33%**

**41,500** TB Cases Missed


**16,000** Death

**Each Day** (Estimated)

**191** New TB Cases

**115** TB Cases Missed

**44** Deaths



Program Indicators	National Level					FY 2077/78 by Province						
	2073/74	2074/75	2075/76	2076/77	2077/78	P-1	Madhesh	Bagmati	Gandaki	Lumbini	Karnali	Sudurpaschim
<b>Number of Service Sites</b>												
DOTS Center	4221	4323	4382	4955	5503	925	1003	1099	657	814	442	563
MDR Treatment Centers	18	21	21	22	22	4	3	2	3	3	2	5
MDR Treatment Sub-Centers	81	86	81	81	81	12	18	24	10	13	2	2
DR Homes	1	1	1	1	1	-	-	-	1	-	-	-
DR Hostel	6	6	6	6	6	1	1	1	-	2	-	1
Microscopy Centers	604	624	604	765	896	83	94	260	61	171	47	180
GeneXpert Facility	27	55	56	72	84	13	18	19	6	17	4	7
Culture Labs and DST	2	2	2	2	2	-	-	2	-	-	-	-
Line Probe Assay (LPA)	2	2	2	2	2	-	-	2	-	-	-	-
<b>TB Case Notification</b>												
Case Notification Rate (All Forms of TB)	111	112	109	93	95	72	105	103	74	115	65	96
Case Notification Rate (PBC New and Relapse)	59	62	62	50	53	39	62	50	37	68	34	60
<b>Types of TB</b>												
PBC	17354	18438	18490	15171	16258	1996	3950	3343	987	3541	627	1814
PCD	5216	4499	4171	3816	3960	430	1251	712	246	872	177	272
EP	9194	9537	9382	8758	8459	1133	1440	2609	643	1508	387	739
New and Relapse TB Cases (Incidence)	30957	31723	31397	27232	28182	3500	6571	6528	1816	5839	1164	2764
<b>Distribution By Age and Sex (%)</b>												
Female	36	37	36	37	38	36	38	41	37	37	36	35
Male	64	63	64	63	62	64	62	59	63	63	64	65
Child (0-14)	5.6	5.5	5.5	6.0	6.6	4.3	9.4	4.7	4.0	7.2	12.1	6.0
Age Group (15-64)	79.6	80	76.6	76.8	75.8	80.4	68.1	83.7	75.8	72.1	74.5	77.6
Age Group (65+)	14.8	14.5	17.9	17.2	17.6	15.3	22.5	11.7	20.2	20.7	13.4	16.5
<b>TB/HIV (%)</b>												
Total HIV Test	54	67	69	51	72	58	56	91	84	74	60	72
Total Positive	1.3	0.9	0.7	0.9	0.8	0.7	0.5	0.5	1.6	0.9	0.7	1.5
Total ART enrollment	93	94	97	92	89	93	100	100	92	92	100	61
<b>Microscopic Examination</b>												
Presumptive Examined	172588	196362	207964	155371	182830	16405	46135	46847	13766	35277	5792	18608
Sputum Positive	13170	12062	10672	8442	10110	1274	2035	2640	525	2118	309	1209
Positivity Rate (%)	7.6	6.1	5.1	5.4	5.5	7.8	4.4	5.6	3.8	6.0	5.3	6.5
# Performing <300 test Per Year				642	766	72	62	232	49	143	41	167
# Performing >= 300 test Per Year				123	130	11	32	28	12	28	6	13
<b>GeneXpert Test</b>												
Total Test performed	21077	40159	70749	47879	69386	10592	6959	14671	4138	20898	3206	8922
MTB Notified	5220	9897	12874	9060	12336	1732	1457	3006	745	3599	367	1430
Rif Resistance Detected	451	641	606	476	569	93	83	102	33	180	18	60
GeneXpert Utilization Rate (%)	23	21	37	19	25	24	12	21	23	37	24	43
Positivity Rate (%)	25	25	18	19	19	17	22	21	19	18	12	17
<b>DSTB Treatment Outcome (%)</b>												
Treatment Success Rate	91	91	91	89	91	90	93	92	91	90	94	89
Death Rate	3	3	3	3.3	3.3	3.1	3.3	2.2	4.5	4.1	2.7	4.2
<b>DR TB Case Notification</b>												
MDR - Shorter Regimen	343	354	232	224	218	39	42	8	21	82	8	18
MDR - Longer Regimen			75	84	126	41	9	25	12	28	2	9
PRE_XDR	86	46	71	68	66	13	2	16	1	29	0	5
XDR	19	20	14	8	8	2	0	1	2	1	0	2
<b>DR TB Treatment Outcome (%)</b>												
Treatment Success Rate	70	67	70	75	73	71	66	72	75	81	67	65
Death Rate	18	17	15	10	13	12	15	6	15	15	-	15

